Literature DB >> 3142843

Enhanced production of the minor components of glidobactins in Polyangium brachysporum.

K Numata1, T Murakami, M Oka, H Yamamoto, M Hatori, T Miyaki, T Oki, H Kawaguchi.   

Abstract

Polyangium brachysporum sp. nov. strain ATCC 53080 produces a novel type of antifungal and antitumor antibiotic complex, glidobactins A, B and C. Enhanced production of minor components, glidobactins B and C, was achieved by medium modification. The addition of soybean oil or corn oil, which are rich in unsaturated C18 fatty acids, to the fermentation medium led to an increased production of components B and C. Productivity of component C was selectively enhanced by the addition of oleic acid-rich oils, olive oil and Tween 80 (polyoxyethylene sorbitan mono-oleate). Furthermore, precursing palmitoleate, linoleate and oleate permitted the direct biosynthesis of components A, B and C, respectively. The fermentation with 3% addition of an appropriate oil at initial time provided an optimal production of component B or C.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142843     DOI: 10.7164/antibiotics.41.1358

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  4 in total

1.  Improvement of glidobactin A production by Polyangium brachysporum.

Authors:  J A Titus; C A Roundy
Journal:  J Ind Microbiol       Date:  1990-11

2.  N-acylation during glidobactin biosynthesis by the tridomain nonribosomal peptide synthetase module GlbF.

Authors:  Heidi J Imker; Daniel Krahn; Jérôme Clerc; Markus Kaiser; Christopher T Walsh
Journal:  Chem Biol       Date:  2010-10-29

3.  Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.

Authors:  Marquicia R Pierce; Reeder M Robinson; Tannya R Ibarra-Rivera; Michael C Pirrung; Nathan G Dolloff; André S Bachmann
Journal:  Leuk Res       Date:  2019-11-12       Impact factor: 3.156

Review 4.  Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.

Authors:  M E Cardenas; M C Cruz; M Del Poeta; N Chung; J R Perfect; J Heitman
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.